Sunshine Biopharma (SBFM)

$1.10 -0.01 (-0.90%)
Market Cap 5.40M
Revenue (ttm) 34.87M
Net Income (ttm) -5.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.71%
Debt to Equity Ratio 0.00
Volume 18,900
Avg Vol 39,356
Day's Range N/A - N/A
Shares Out 4.91M
Stochastic %K 33%
Beta 1.51
Analysts Strong Sell
Price Target $7.00

Company Profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pa...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 954 330 0684
Address:
333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, United States
Pomacanthus
Pomacanthus Mar. 15 at 12:52 PM
$SBFM just think only .11c away from the next RS and you can witness shorts coming out from the woodwork, might even include me. Count on at least -50% post split based on previous history. It ain’t easy achieving-98% dilution…
1 · Reply
MB66
MB66 Mar. 13 at 2:26 PM
$SBFM volume up on SBFMW (Tradeable Warrants)
1 · Reply
Kalini67
Kalini67 Mar. 13 at 12:50 PM
$SBFM Do not Panic they trying to flush weak hands out, nothing to see here, just few more weeks of pain, Endure and be Brave!
0 · Reply
Paxter
Paxter Mar. 13 at 12:19 PM
$SBFM im pretty sure im one of the Biggest Loser out here 90k loss too many rs
3 · Reply
Kalini67
Kalini67 Mar. 12 at 11:08 PM
$SBFM No R/S, I called Aegis to know or to understand the term if warrants and they said there is nothing on the table yet, Sooooooooo is getting more interesting, they filed the 8K to cover their butts nothing else, I’ll see you on the other side”
1 · Reply
Masterrunner
Masterrunner Mar. 12 at 10:44 PM
$SBFM Hard truth: leave before the next RS. If you’ve been here long enough, you know exactly how this movie ends. Coming from a former perma-bull with a conscience. NFA. GLTA.
0 · Reply
thegoodnessparadox
thegoodnessparadox Mar. 12 at 9:01 PM
$SBFM Under the 2025 rule changes, Nasdaq now has explicit authority to refuse to allow a reverse split if the company has recently used one or is viewed as abusing reverse splits to maintain compliance.
5 · Reply
Pomacanthus
Pomacanthus Mar. 12 at 1:11 PM
$SBFM history predicts this will dwindle down slowly to sub $1 so they use compliance excuse to RS, thats the good Drs fav thing to do. He never uses lube btw. I love that buy recommendation posted from Schwab. Down -100% buy you should buy it anyway 😭
3 · Reply
hotslots
hotslots Mar. 12 at 1:17 AM
$SBFM almost 6 months with no pr. If contra is right then hallelujah! If not i cant even imagine. I pray for all of us
2 · Reply
Ejannsen
Ejannsen Mar. 11 at 10:36 PM
$SBFM If Ageis involved in any way it’s a pump and dump set up. All this company can do is scam, reverse split, rinse and repeat. Dr Shitty is a scam artist.
0 · Reply
Latest News on SBFM
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Oct 28, 2025, 2:10 PM EDT - 4 months ago

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Oct 28, 2025, 7:45 AM EDT - 4 months ago

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Oct 20, 2025, 7:45 AM EDT - 5 months ago

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin

Oct 16, 2025, 7:45 AM EDT - 5 months ago

Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

Oct 14, 2025, 10:45 AM EDT - 5 months ago

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

Oct 14, 2025, 8:50 AM EDT - 5 months ago

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience

Oct 14, 2025, 7:00 AM EDT - 5 months ago

Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

Oct 9, 2025, 8:00 AM EDT - 5 months ago

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Jul 2, 2025, 8:00 AM EDT - 9 months ago

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Jun 11, 2025, 8:30 AM EDT - 9 months ago

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 15, 2025, 4:15 PM EDT - 10 months ago

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

May 6, 2025, 8:30 AM EDT - 11 months ago

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Apr 21, 2025, 8:30 AM EDT - 11 months ago

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Apr 3, 2025, 10:50 AM EDT - 1 year ago

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Apr 2, 2025, 1:20 PM EDT - 1 year ago

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Apr 2, 2025, 11:35 AM EDT - 1 year ago

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Apr 1, 2025, 5:09 PM EDT - 1 year ago

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Mar 10, 2025, 9:00 AM EDT - 1 year ago

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Jan 21, 2025, 8:00 AM EST - 1 year ago

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Jan 15, 2025, 8:00 AM EST - 1 year ago

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Dec 9, 2024, 7:30 AM EST - 1 year ago

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Sunshine Biopharma Launches a New Generic Prescription Drug

Dec 4, 2024, 4:05 PM EST - 1 year ago

Sunshine Biopharma Launches a New Generic Prescription Drug

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Dec 2, 2024, 8:00 AM EST - 1 year ago

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Nov 6, 2024, 8:00 AM EST - 1 year ago

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Sunshine Biopharma Announces Reverse Stock Split

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Reverse Stock Split

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Feb 15, 2024, 9:15 AM EST - 2 years ago

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Feb 13, 2024, 9:00 AM EST - 2 years ago

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma Moves Principal Office to New York City

Dec 4, 2023, 8:30 AM EST - 2 years ago

Sunshine Biopharma Moves Principal Office to New York City

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Nov 13, 2023, 8:30 AM EST - 2 years ago

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sep 21, 2023, 9:05 PM EDT - 2 years ago

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aug 11, 2023, 8:30 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

May 16, 2023, 2:15 PM EDT - 3 years ago

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

May 16, 2023, 9:58 AM EDT - 3 years ago

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

May 12, 2023, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

May 11, 2023, 9:00 AM EDT - 3 years ago

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Apr 5, 2023, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Feb 28, 2023, 7:30 AM EST - 3 years ago

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Feb 10, 2023, 7:35 AM EST - 3 years ago

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Sunshine Biopharma Announces Share Repurchase Program

Jan 19, 2023, 7:30 AM EST - 3 years ago

Sunshine Biopharma Announces Share Repurchase Program

Sunshine Biopharma's Annual Letter to Shareholders

Dec 20, 2022, 8:00 AM EST - 3 years ago

Sunshine Biopharma's Annual Letter to Shareholders

4 Stocks Meeting GuruFocus' Value Screens in December

Dec 5, 2022, 5:46 PM EST - 3 years ago

4 Stocks Meeting GuruFocus' Value Screens in December

RM CACC WFG

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Nov 16, 2022, 8:00 AM EST - 3 years ago

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Pomacanthus
Pomacanthus Mar. 15 at 12:52 PM
$SBFM just think only .11c away from the next RS and you can witness shorts coming out from the woodwork, might even include me. Count on at least -50% post split based on previous history. It ain’t easy achieving-98% dilution…
1 · Reply
MB66
MB66 Mar. 13 at 2:26 PM
$SBFM volume up on SBFMW (Tradeable Warrants)
1 · Reply
Kalini67
Kalini67 Mar. 13 at 12:50 PM
$SBFM Do not Panic they trying to flush weak hands out, nothing to see here, just few more weeks of pain, Endure and be Brave!
0 · Reply
Paxter
Paxter Mar. 13 at 12:19 PM
$SBFM im pretty sure im one of the Biggest Loser out here 90k loss too many rs
3 · Reply
Kalini67
Kalini67 Mar. 12 at 11:08 PM
$SBFM No R/S, I called Aegis to know or to understand the term if warrants and they said there is nothing on the table yet, Sooooooooo is getting more interesting, they filed the 8K to cover their butts nothing else, I’ll see you on the other side”
1 · Reply
Masterrunner
Masterrunner Mar. 12 at 10:44 PM
$SBFM Hard truth: leave before the next RS. If you’ve been here long enough, you know exactly how this movie ends. Coming from a former perma-bull with a conscience. NFA. GLTA.
0 · Reply
thegoodnessparadox
thegoodnessparadox Mar. 12 at 9:01 PM
$SBFM Under the 2025 rule changes, Nasdaq now has explicit authority to refuse to allow a reverse split if the company has recently used one or is viewed as abusing reverse splits to maintain compliance.
5 · Reply
Pomacanthus
Pomacanthus Mar. 12 at 1:11 PM
$SBFM history predicts this will dwindle down slowly to sub $1 so they use compliance excuse to RS, thats the good Drs fav thing to do. He never uses lube btw. I love that buy recommendation posted from Schwab. Down -100% buy you should buy it anyway 😭
3 · Reply
hotslots
hotslots Mar. 12 at 1:17 AM
$SBFM almost 6 months with no pr. If contra is right then hallelujah! If not i cant even imagine. I pray for all of us
2 · Reply
Ejannsen
Ejannsen Mar. 11 at 10:36 PM
$SBFM If Ageis involved in any way it’s a pump and dump set up. All this company can do is scam, reverse split, rinse and repeat. Dr Shitty is a scam artist.
0 · Reply
Kalini67
Kalini67 Mar. 11 at 9:35 PM
$SBFM Every single day that passes without news make me extremely
1 · Reply
MB66
MB66 Mar. 11 at 12:09 AM
$SBFM haven’t had a chance to look this over, but just came across this report from today from LSEG. It’s on my Scwab account under Analyst Reports. Not sure there’s a link to it somewhere that we could post up? It’s 12 pages, overall, the give it a Buy rating. This is the fist legit looking analyst report I’ve seen come out covering this stock. Only other one was the Bull 💩 Aegis report tryin to pump.
4 · Reply
MB66
MB66 Mar. 10 at 11:24 PM
$SBFM up as much as .08 Cents today! Yea!!!! Only need $80 a share to get my money back!! Better be soon, another RS is gonna make it way less obtainable….
2 · Reply
contra7
contra7 Mar. 10 at 5:45 PM
$SBFM 26k print at 12:12 ….the quiet accumulation on low volume continues. I won’t be surprised if another institution is added later on today.
4 · Reply
Kalini67
Kalini67 Mar. 10 at 4:39 PM
$SBFM I just Hope and bring hope to others!
0 · Reply
thegoodnessparadox
thegoodnessparadox Mar. 10 at 4:34 PM
$SBFM What are the terms for the warrants? I would like to know. Hint, hint.
0 · Reply
contra7
contra7 Mar. 10 at 3:59 PM
$SBFM This latest filing was headed “Personal and Confidential”. An NDA is just that and nothing regarding a potential deal can be communicated through any filings until the date of announcement that’s why they are worded very carefully. Notice the vertical structure of the CEOs name, this is not a standard dilution or capital raise filing.
2 · Reply
RonRon1234
RonRon1234 Mar. 10 at 2:52 PM
$SBFM guess we wait for March 31st to April 7th for earning or buyout or something...
0 · Reply
Ejannsen
Ejannsen Mar. 10 at 1:48 AM
$SBFM
0 · Reply
Ejannsen
Ejannsen Mar. 10 at 1:47 AM
$SBFM
0 · Reply
MB66
MB66 Mar. 9 at 10:35 PM
$SBFM these clowns don’t PR anything anymore… https://fintel.io/doc/sec-sunshine-biopharma-inc-1402328-ex991-2026-march-09-20521-1960
2 · Reply
Kalini67
Kalini67 Mar. 9 at 9:59 PM
$SBFM Well there is another clue they are cleaning the overhang by inducing exercise of warrants, Thanks Dr, am waiting for you!
3 · Reply